Delhi High Court restrains generic pharmaceutical companies from making, selling Novartis' patented drug

The injunction order was passed against generic pharmaceutical companies that were manufacturing or selling Valsartan and Sacubitril tablets, a patented combination used to treat cardiovascular diseases.
Delhi High Court
Delhi High Court

The Delhi High Court recently passed an injunction order restraining a slew of generic pharmaceutical firms including Windlas Biotech, Natco and Torrent Pharma from manufacturing or selling Valsartan and Sacubitril Tablets, patented in favour of Novartis (Novartis AG & Ors. v. NATCO Pharma Limited)

Want to read the full story?

We’re glad you’re enjoying this story. Subscribe to any of our plans to continue reading the story.

Already have an account? Sign In

Related Stories

No stories found.
Bar and Bench - Indian Legal news